• Western blot analysis of various lysates using SLC7A8 Rabbit polyclonal antibody (STJ117061) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 10s.

Anti-SLC7A8 antibody (150-250) (STJ117061)

SKU:
STJ117061

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-SLC7A8 (150-250) is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: SLC7A8
Gene ID: 23428
Uniprot ID: LAT2_HUMAN
Immunogen Region: 150-250
Immunogen: A synthetic peptide corresponding to a sequence within amino acids 150-250 of human SLC7A8 (NP_036376.2).
Immunogen Sequence: LFPTCFPPESGLRLLAAICL LLLTWVNCSSVRWATRVQDI FTAGKLLALALIIIMGIVQI CKGEYFWLEPKNAFENFQEP DIGLVALAFLQGSFAYGGWN F
Tissue Specificity Strongest expression is observed in kidney and moderate expression in placenta and brain, followed by liver, prostate, testis, ovary, lymph node, thymus, spleen, skeletal muscle and heart. Also expressed in fetal liver as well as in the retinal pigment epithelial cell line ARPE-19 and the intestinal epithelial cell line Caco-2.
Function Associates with SLC3A2 to form a functional heterodimeric complex that translocates small and large neutral amino acids with broad specificity and a stoichiometry of 1:1. Functions as amino acid antiporter mediating the influx of extracellular essential amino acids mainly in exchange with the efflux of highly concentrated intracellular amino acids. Has relatively symmetrical selectivities but strongly asymmetrical substrate affinities at both the intracellular and extracellular sides of the transporter. This asymmetry allows SLC7A8 to regulate intracellular amino acid pools (mM concentrations) by exchange with external amino acids (uM concentration range), equilibrating the relative concentrations of different amino acids across the plasma membrane instead of mediating their net uptake. May play an essential role in the reabsorption of neutral amino acids from the epithelial cells to the bloodstream in the kidney. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. Imports the thyroid hormone diiodothyronine (T2) and to a smaller extent triiodothyronine (T3) but not rT 3 or thyroxine (T4). Mediates the uptake of L-DOPA. May participate in auditory function.
Protein Name Large Neutral Amino Acids Transporter Small Subunit 2
L-Type Amino Acid Transporter 2
Hlat2
Solute Carrier Family 7 Member 8
Database Links Reactome: R-HSA-210991
Reactome: R-HSA-352230
Cellular Localisation Cell Membrane
Multi-Pass Membrane Protein
Basolateral Cell Membrane
Localized To The Cytoplasm When Expressed Alone But When Coexpressed With Slc3a2/4f2hc
Is Localized To The Plasma Membrane
Colocalized With Slc3a2/4f2hc At The Basolateral Membrane Of Kidney Cortex Proximal Tubules And Small Intestine Epithelia Of The Villi
Alternative Antibody Names Anti-Large Neutral Amino Acids Transporter Small Subunit 2 antibody
Anti-L-Type Amino Acid Transporter 2 antibody
Anti-Hlat2 antibody
Anti-Solute Carrier Family 7 Member 8 antibody
Anti-SLC7A8 antibody
Anti-LAT2 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance